About
About this Poster:
Efpeglenatide is a long-acting GLP-1 R agonist in development for the treatment of type 2 diabetes. Efpeglenatide’s effects on the GLP-1 R suggest that it is a superagonist: a ligand that leads to greater maximal signalling and stimulation compared with the endogenous ligand.
![In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide versus other Glucagon-Like Peptide-1 Receptor Agonists thumbnail](https://prosciento.com/wp-content/uploads/2022/01/poster-18.png)